Detalhe da pesquisa
1.
Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial.
Sci Bull (Beijing)
; 68(20): 2448-2455, 2023 10 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37743201